exRNAdisease

Entry Detail

---



General Information

Database ID: exR0357710 RNA Name: hsa-miR-516b-5p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53736860 End Site(bp): 53736881 External Links: hsa-miR-516b-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCL2L11 chr2 111119378 111168445 + CHKB-CPT1B chr22 50568869 50582965 - CPT1B chr22 50568861 50578465 - DNAJC9 chr10 73183362 73247255 - FAM13B chr5 137937960 138051961 - FNBP4 chr11 47716494 47767443 - FOSL2 chr2 28392448 28417317 + FSD1 chr19 4304598 4323843 + GOLGA1 chr9 124878275 124948492 - HIF1AN chr10 100529072 100559998 + MAK16 chr8 33485182 33501262 + NEMP1 chr12 57055643 57088063 - NID1 chr1 235975830 236065109 - PIGS chr17 28553383 28571794 - QSER1 chr11 32892820 32993316 + RABGAP1 chr9 122940833 123104866 + S100A16 chr1 153606886 153613145 - SGPP1 chr14 63684216 63728065 - STAT3 chr17 42313324 42388568 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000698 chr16 47531309 47549512 + hsa_circ_0001727 chr7 99621041 99621930 + hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000825 chr18 8718421 8720494 + hsa_circ_0001387 chr4 1902352 1936989 + hsa_circ_0000038 chr1 28800065 28802803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC079781.5 chr7 97851688 97972985 - AL157392.3 chr10 13631143 13668445 + COL4A2-AS2 chr13 110456396 110463287 - LINC00324 chr17 8220642 8224043 - LINC01184 chr5 127939152 128083172 - MIR194-2HG chr11 64889560 64893449 - NEAT1 chr11 65422774 65445540 + PCBP1-AS1 chr2 69962263 70103220 - TBC1D3P1-DHX40P1 chr17 59962363 60018975 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.